Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study
Open Access
- 6 May 2019
- journal article
- research article
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 17 (1) , 80
Abstract
This study aims to describe the short-term reactogenicity of the AS03-adjuvanted H5N1 vaccine expressed through adverse events (AEs) and quality-adjusted life-day (QALD) scores. The AEs are likely to be short-term and therefore the quality of life (QoL) questionnaire, SF-36v2, was administered daily to record changes over seven days. A more sensitive application of this instrument should allow for a better understanding of short-term tolerability of adjuvanted vaccines. Participants (N = 50) received a 2-dose vaccination schedule. Solicited (collected daily: days 0 to 7 [post dose 1] and 21 to 28 [post dose 2]) and unsolicited (collected weekly until day 21) AEs were collected via diary cards. The QoL questionnaires were completed daily (days 0–6) and weekly (days 0, 6, 21, 27) after dose one. Questionnaire data were transformed into SF-6D scores to report QALDs. It was hypothesized post-hoc that the QALD and daily AEs scores should correlate if discrete QoL-changes were captured. Pain (92%) and muscle ache (66%) were the most commonly reported solicited local and general AEs respectively, neither increased in intensity nor in frequency after dose 2. No safety concerns were identified during the study. A correlation between the daily AEs and QALD scores existed (correlation coefficient, − 0.97 (p < 0.001)). The impact of the AEs scores on the QALD was marginal (− 0.02 max for one day). Similarly with other H5N1 studies, no safety concern was identified throughout the study. Some time-limited variations in QALD-scores were reported. Our results imply that daily administration of the SF-36v2 captures changes in QALD-scores. ClinicalTrials.gov . NCT01788228. Registered 11 February 2013.Keywords
Funding Information
- Biomedical Advanced Research and Development Authority (HHSO100200700029C)
This publication has 13 references indexed in Scilit:
- Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularlyHuman Vaccines & Immunotherapeutics, 2016
- Key roles of adjuvants in modern vaccinesNature Medicine, 2013
- Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA StudyPLOS ONE, 2013
- Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trialVaccine, 2013
- Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized StudyThe Journal of Infectious Diseases, 2011
- Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunityVaccine, 2011
- Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α AgentsJAMA, 2009
- Response shift masks the treatment impact on patient reported outcomes (PROs): the example of individual quality of life in edentulous patientsHealth and Quality of Life Outcomes, 2005
- Quality of life assessment using the short form 12 questionnaire is as reliable and sensitive as the short form 36 in distinguishing symptom severity in myocardial infarction survivorsHeart, 2003
- The estimation of a preference-based measure of health from the SF-36Journal of Health Economics, 2002